These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 35315393)

  • 41. SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.
    Ghiffari A; Anwar C; Hasyim H; Iskandar I; Kamaluddin MT
    Acta Biomed; 2022 Mar; 93(1):e2022018. PubMed ID: 35315393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genome Profiling of SARS-CoV-2 in Indonesia, ASEAN and the Neighbouring East Asian Countries: Features, Challenges and Achievements.
    Cahyani I; Putro EW; Ridwanuloh AM; Wibowo S; Hariyatun H; Syahputra G; Akbariani G; Utomo AR; Ilyas M; Loose M; Kusharyoto W; Susanti S
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2 transmissibility compared between variants of concern and vaccination status.
    Wang L; Didelot X; Bi Y; Gao GF
    Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35062017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Viruses, variants and vaccines.
    Cowan DA; Burton SG; Rybicki EP; Wiliamson AL; Dorrington RA; Pepper MS
    S Afr Med J; 2021 Mar; 111(5):409-411. PubMed ID: 34852879
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    Lopez Bernal J; Andrews N; Gower C; Gallagher E; Simmons R; Thelwall S; Stowe J; Tessier E; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown KE; Hopkins S; Chand M; Ramsay M
    N Engl J Med; 2021 Aug; 385(7):585-594. PubMed ID: 34289274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lifting of COVID-19 restrictions in the UK and the Delta variant.
    Burki TK
    Lancet Respir Med; 2021 Aug; 9(8):e85. PubMed ID: 34265238
    [No Abstract]   [Full Text] [Related]  

  • 48. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
    Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Hasan MR; Malek JA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Al Khal A; Butt AA; Bertollini R; Abu-Raddad LJ
    Nat Med; 2021 Sep; 27(9):1614-1621. PubMed ID: 34244681
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
    Liu C; Ginn HM; Dejnirattisai W; Supasa P; Wang B; Tuekprakhon A; Nutalai R; Zhou D; Mentzer AJ; Zhao Y; Duyvesteyn HME; López-Camacho C; Slon-Campos J; Walter TS; Skelly D; Johnson SA; Ritter TG; Mason C; Costa Clemens SA; Gomes Naveca F; Nascimento V; Nascimento F; Fernandes da Costa C; Resende PC; Pauvolid-Correa A; Siqueira MM; Dold C; Temperton N; Dong T; Pollard AJ; Knight JC; Crook D; Lambe T; Clutterbuck E; Bibi S; Flaxman A; Bittaye M; Belij-Rammerstorfer S; Gilbert SC; Malik T; Carroll MW; Klenerman P; Barnes E; Dunachie SJ; Baillie V; Serafin N; Ditse Z; Da Silva K; Paterson NG; Williams MA; Hall DR; Madhi S; Nunes MC; Goulder P; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR
    Cell; 2021 Aug; 184(16):4220-4236.e13. PubMed ID: 34242578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
    Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
    Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 Variants and Vaccines.
    Krause PR; Fleming TR; Longini IM; Peto R; Briand S; Heymann DL; Beral V; Snape MD; Rees H; Ropero AM; Balicer RD; Cramer JP; Muñoz-Fontela C; Gruber M; Gaspar R; Singh JA; Subbarao K; Van Kerkhove MD; Swaminathan S; Ryan MJ; Henao-Restrepo AM
    N Engl J Med; 2021 Jul; 385(2):179-186. PubMed ID: 34161052
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
    Wall EC; Wu M; Harvey R; Kelly G; Warchal S; Sawyer C; Daniels R; Hobson P; Hatipoglu E; Ngai Y; Hussain S; Nicod J; Goldstone R; Ambrose K; Hindmarsh S; Beale R; Riddell A; Gamblin S; Howell M; Kassiotis G; Libri V; Williams B; Swanton C; Gandhi S; Bauer DL
    Lancet; 2021 Jun; 397(10292):2331-2333. PubMed ID: 34090624
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Pormohammad A; Zarei M; Ghorbani S; Mohammadi M; Razizadeh MH; Turner DL; Turner RJ
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34066475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transmission dynamics of novel Coronavirus-SARS-CoV-2 in South Sumatera, Indonesia.
    Sitorus RJ; Wathan I; Ridwan H; Wibisono H; Nuraini L; Yusri ; Kosim G; Nurdin N; Mamat H; Andrayani I; Antara NY; Natalia M
    Clin Epidemiol Glob Health; 2021; 11():100777. PubMed ID: 34027231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.
    Ramanathan M; Ferguson ID; Miao W; Khavari PA
    Lancet Infect Dis; 2021 Aug; 21(8):1070. PubMed ID: 34022142
    [No Abstract]   [Full Text] [Related]  

  • 56. Controlling COVID-19 via test-trace-quarantine.
    Kerr CC; Mistry D; Stuart RM; Rosenfeld K; Hart GR; Núñez RC; Cohen JA; Selvaraj P; Abeysuriya RG; Jastrzębski M; George L; Hagedorn B; Panovska-Griffiths J; Fagalde M; Duchin J; Famulare M; Klein DJ
    Nat Commun; 2021 May; 12(1):2993. PubMed ID: 34017008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2.
    McDonald I; Murray SM; Reynolds CJ; Altmann DM; Boyton RJ
    NPJ Vaccines; 2021 May; 6(1):74. PubMed ID: 33986272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?
    Guo S; Liu K; Zheng J
    Int J Biol Sci; 2021; 17(6):1476-1485. PubMed ID: 33907511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.
    Wang P; Casner RG; Nair MS; Wang M; Yu J; Cerutti G; Liu L; Kwong PD; Huang Y; Shapiro L; Ho DD
    Cell Host Microbe; 2021 May; 29(5):747-751.e4. PubMed ID: 33887205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Behavioral changes before lockdown and decreased retail and recreation mobility during lockdown contributed most to controlling COVID-19 in Western countries.
    Deforche K; Vercauteren J; Müller V; Vandamme AM
    BMC Public Health; 2021 Apr; 21(1):654. PubMed ID: 33823820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.